Every financial statement,
one clean chart.
Search any US-listed company. Data straight from SEC filings.
BridgeBio Pharma, Inc. (BBIO), most recent 12 months reported: revenue $713.07M, net loss $691.87M, free cash flow -$435.39M. Latest balance sheet on file: liquid cash $720.16M, total debt $2.48B, net cash -$1.76B. From SEC filings. More on BridgeBio Pharma, Inc.: Revenue · Profitability · Cash flow · Debt Others in Pharmaceutical Preparations: Kiniksa Pharmaceuticals International, plc · PACIRA BIOSCIENCES, INC. · Amphastar Pharmaceuticals, Inc. · ULTRAGENYX PHARMACEUTICAL INC. · NURIX THERAPEUTICS, INC. · ARROWHEAD PHARMACEUTICALS, INC. · Mirum Pharmaceuticals, Inc. · TRAVERE THERAPEUTICS, INC.
Filter every US company by the numbers — net cash, margins, ROIC, growth. Looking for one company? The search box above is free.
Follow a company and we'll email you when it files a quarterly or annual report with the SEC. Free follows 3 companies; Pro follows up to 500, and sorts and filters them.